Candel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CADL
Candel Therapeutics, Inc. (CADL) Piotroski F-score
Candel Therapeutics, Inc.'s Piotroski F-score for fiscal 2022 is 1 out of 9: 1 of nine tests of profitability, leverage and efficiency passed, down from 3 in fiscal 2021.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 1 | (2.00) |
| FY2021 | 3 | — |
How fiscal 2022’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (22.52%) | (56.67%) | Fail | 0 |
| Positive operating cash flow | (31.42m) | (22.22m) | Fail | 0 |
| Rising return on assets | (22.52%) | (56.67%) | Pass | 1 |
| Cash flow above net income | (12.62m) | 13.91m | Fail | 0 |
| Falling long-term leverage | 0.25 | 0.01 | Fail | 0 |
| Rising current ratio | 12.81 | 15.84 | Fail | 0 |
| No new shares issued | 28,823,500 | 18,873,100 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.00 | 0.00 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 1 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| PHAR Pharming Group N.V. Sponsored ADR compare | 5 |
| MDXG MiMedx Group, Inc compare | 5 |
| GYRE Gyre Therapeutics, Inc. compare | 4 |
| OABI OmniAb, Inc. compare | 2 |
| CADL Candel Therapeutics, Inc. | 1 |
| AURA Aura Biosciences, Inc. compare | — |
| DSGN Design Therapeutics, Inc. compare | — |
| ANNX Annexon, Inc. compare | — |
| PRME Prime Medicine, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover